Bedaquiline is currently a key drug for treating multidrug-resistant or rifampin-resistant tuberculosis. We report and discuss the unusual development of resistance to bedaquiline in a teenager in Namibia, despite an optimal background regimen and adherence. The report highlights the risk for bedaquiline resistance development and the need for rapid drug-resistance testing.
Keywords: MDR TB; Namibia; TB; antimicrobial resistance; bacteria; bedaquiline; respiratory infections; tuberculosis; tuberculosis and other mycobacteria.